Activity was seen with lenvatinib plus a weekly dose of paclitaxel in patients with recurrent endometrial and platinum-resistant epitherlial ovarian cancer, according to a presentation at the 50th SGO Annual Meeting. The combination resulted in a 65% overall response rate in a phase I trial.
Floor J. Backes, MD, discusses the results from a phase I trial investigating the combination of lenvatinib (Lenvima) and paclitaxel in patients with recurrent ovarian, fallopian tube, or peritoneal cancers.
Patients with high-risk ovarian cancer being treated with niraparib experienced a decrease in adverse events when treated with a 200- or 300-mg individualized starting dose based on bodyweight and platelet count compared with patients who received a fixed starting dose of 300 mg, according to data from a recent analysis of the ongoing ENGOT-OV26/PRIMA study.
Repeated use of PARP inhibitors may be a beneficial treatment strategy in the future for women with recurrent epithelial ovarian cancer, according to the results of a retrospective, multi-institutional study presented at the 2019 SGO Annual Meeting. The findings suggested that prior exposure to PARP inhibition may not lead to resistance, which could lead to increased use of repeat PARP treatment going forward.
Treatment with maintenance niraparib led to extended progression-free survival time in patients with recurrent ovarian cancer without the patients experiencing symptoms or toxicity compared with placebo, according to results of an analysis from the phase III ENGOT-OV16/NOVA trial. In patients with germline <em>BRCA</em>-mutated disease, the benefit was increased 4-fold and in patients non–germline <em>BRCA</em>-mutated ovarian cancer the benefit was increased 2-fold.
Tanya Dorff, MD, discusses recent data with olaparib (Lynparza) in castration-resistant prostate cancer and the future role of PARP inhibitors in this disease.<br />
First-line treatment with single-agent pembrolizumab induced a 24.8% overall response rate in patients with non-clear cell renal cell carcinoma, according to findings from cohort B of the phase II KEYNOTE-427 trial that were presented during the 2019 Genitourinary Cancers Symposium.<br />
According to phase I findings from a dose-escalation cohort presented during the 2019 Genitourinary Cancers Symposium, the combination of pembrolizumab and cabozantinib demonstrated antitumor activity in patients with previously treated metastatic renal cell carcinoma and is tolerated at their approved doses for this indication.
Retrospective findings reported during the 2019 Genitourinary Cancers Symposium showed patients with metastatic castration-resistant prostate cancer who received radium-223 dichloride with abiraterone acetate in a layered fashion experienced a lower rate of symptomatic skeletal events compared with those who received the treatments concurrently.
Adding enzalutamide (Xtandi) to androgen deprivation therapy led to prolonged radiographic progression-free survival compared with ADT alone in men with metastatic hormone-sensitive prostate cancer, investigators reported during the 2019 Genitourinary Cancers Symposium.
According to data from the phase III ARAMIS trial presented during the 2019 Genitourinary Cancers Symposium, darolutamide added to androgen deprivation therapy significantly improved metastasis-free survival compared with placebo plus ADT in patients with nonmetastatic castration-resistant prostate cancer.
Raoul S. Concepcion, MD, FACS, director, Comprehensive Prostate Center, discusses takeaways from the ARAMIS study of darolutamide in patients with nonmetastatic castration-resistant prostate cancer.
In updated 30-month follow-up data from the phase III CheckMate-214 trial, nivolumab combined with low-dose ipilimumab sustained strong responses and a survival benefit as a frontline treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma.
Although African-American men are at a higher risk for metastatic castration-resistant prostate cancer and have worse survival outcomes compared with Caucasian men, findings of a recent retrospective study suggested they may have a better response to several prostate cancer treatments.
Findings from the phase III KEYNOTE-426 study demonstrated a significantly improved progression-free survival and overall survival with the combination pembrolizumab plus axitinib versus sunitinib in previously-untreated patients with clear cell metastatic renal cell carcinoma, according to a prescast ahead of the 2019 Genitourinary Cancers Symposium.
Treatment with the novel targeted radiation therapy lutetium-177 PSMA-617 demonstrated strong clinical activity and the potential to improve survival in heavily pretreated men with PSMA-positive metastatic castration-resistant prostate cancer, according to phase II findings to be presented at the 2019 Genitourinary Cancers Symposium.
Achieving an objective response to TKI therapy was associated with longer overall survival in patients with previously untreated hepatocellular carcinoma, according to findings of a retrospective analysis presented during the 2019 Gastrointestinal Cancers Symposium.
Michael J. Overman, MD, discusses the data presented at the 2019 Gastrointestinal Cancers Symposium for the phase II CheckMate-142 in previously treated patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.
When durvalumab and tremelimumab were combined with best supportive care, the combination reduced the risk of progression or death by 28% compared with best supportive care alone, according to findings from a phase II clinical trial.
Updated findings from the safety lead-in phase of the BEACON CRC trial showed an estimated survival time beyond historic controls from treatment with a triplet combination of encorafenib, binimetinib, and cetuximab for patients with <em>BRAF </em>V600E-mutant metastatic colorectal cancer.
Regorafenib reduced the risk of progression by 51% compared with placebo in patients with metastatic or unresectable biliary tract cancer who were previously treated with gemcitabine and platinum-based chemotherapy, according to results from the phase II REACHIN trial that were presented at the 2019 Gastrointestinal Cancers Symposium.
Combined BRAF and MEK inhibition induced a promising response rate and survival rates among patients with <em>BRAF </em>V600E–mutated biliary tract cancer (BTC), according to the results of the ROAR trial that were presented during the 2019 Gastrointestinal Cancers Symposium.
Treatment with TAS-102 led to an improvement in overall survival among patients with metastatic gastric/gastroesophageal junction cancer. The improvement was also seen both in patients who had and had not undergone prior gastrectomy, according to a subgroup analysis from the phase III TAGS study.
Pashtoon M. Kasi, MD, MBBS, MS, discusses how the triplet regimen of the BRAF inhibitor encorafenib, the MEK inhibitor binimetinib, and the EGFR inhibitor cetuximab, will impact the treatment landscape for patients with metastatic colorectal cancer.
Based on findings from the phase I/II NivoRam study, investigators at the 2019 Gastrointestinal Cancers Symposium reported that the combination of nivolumab and ramucirumab is active in patients with previously treated advanced gastric adenocarcinoma.
In findings reported at the 2019 Gastrointestinal Cancers Symposium, 67% of patients with untreated metastatic HER2-positive esophagogastric adenocarcinoma treated with the combination of pembrolizumab, trastuzumab, and chemotherapy remained progression-free at 6 months.
According to findings from the KEYNOTE-181 trial, pembrolizumab demonstrated a significant improvement in overall survival in patients with PD-L1–positive advanced or metastatic esophageal or esophageal junction carcinoma who progressed on standard therapy, marking the first time a PD-1 inhibitor has demonstrated a survival improvement in this patient population.
Based on data from the phase III TAM-01 trial presented at the 41st Annual San Antonio Breast Cancer Symposium, investigators concluded that giving women diagnosed with breast intraepithelial neoplasia a lower dose of tamoxifen following surgery could be as effective and less toxic than the current standard dose.
Charles E. Geyer, Jr, MD, professor of medicine at Virginia Commonwealth University School of Medicine, associate director for clinical research and Harrigan, Haw, Luck Families Chair in Cancer Research at Massey Cancer Center, discusses the impact of pertuzumab (Perjeta) in the treatment of patients with HER2-positive breast cancer at the 2018 San Antonio Breast Cancer Symposium.
At the 2018 San Antonio Breast Cancer Symposium, data demonstrated that use of circulating tumor-cell counts had strong value for selecting endocrine therapy compared to chemotherapy in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer.